RPL17 and non-small cell lung carcinoma: In Part 1, durvalumab was combined with cisplatin, carboplatin, or pemetrexed; in Part 3, the PD-1/CTLA-4 bispecific antibody MEDI5752 was combined with carboplatin; and in Part 4, T DXd is being tested with rilvegostomig, a PD 1/TIGIT bispecific antibody, with or without carboplatin, in previously untreated HER2 overexpressing NSCLC.